Search

Your search keyword '"Ishidoya, Shigeto"' showing total 496 results
Start Over Author "Ishidoya, Shigeto" Publication Year Range Last 50 years
496 results on '"Ishidoya, Shigeto"'

3. The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study

Author

Okita, Kazutaka, Hatakeyama, Shingo, Narita, Shintaro, Takahashi, Masahiro, Sakurai, Toshihiko, Kawamura, Sadafumi, Hoshi, Senji, Ishida, Masanori, Kawaguchi, Toshiaki, Ishidoya, Shigeto, Shimoda, Jiro, Sato, Hiromi, Mitsuzuka, Koji, Ito, Akihiro, Tsuchiya, Norihiko, Arai, Yoichi, Habuchi, Tomonori, and Ohyama, Chikara

Published
2020
Full Text
View/download PDF

5. Clinical Characterization of Low Prostate-specific Antigen on Prognosis in Patients With Metastatic Castration-naive Prostate Cancer

Author

Kodama, Hirotake, Hatakeyama, Shingo, Narita, Shintaro, Takahashi, Masahiro, Sakurai, Toshihiko, Kawamura, Sadafumi, Hoshi, Senji, Ishida, Masanori, Kawaguchi, Toshiaki, Ishidoya, Shigeto, Shimoda, Jiro, Narita, Takuma, Sato, Hiromi, Mitsuzuka, Koji, Tochigi, Tatsuo, Tsuchiya, Norihiko, Arai, Yoichi, Habuchi, Tomonori, and Ohyama, Chikara

Published
2019
Full Text
View/download PDF

6. Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan

Author

Narita, Shintaro, Hatakeyama, Shingo, Takahashi, Masahiro, Sakurai, Toshihiko, Kawamura, Sadafumi, Hoshi, Senji, Ishida, Masanori, Kawaguchi, Toshiaki, Ishidoya, Shigeto, Shimoda, Jiro, Sato, Hiromi, Koizumi, Atsushi, Mitsuzuka, Koji, Tochigi, Tatsuo, Tsuchiya, Norihiko, Ohyama, Chikara, Arai, Yoichi, Nomura, Kyoko, and Habuchi, Tomonori

Published
2020
Full Text
View/download PDF

7. Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate Cancer

Author

Akamatsu, Shusuke, Kubota, Masashi, Uozumi, Ryuji, Narita, Shintaro, Takahashi, Masahiro, Mitsuzuka, Koji, Hatakeyama, Shingo, Sakurai, Toshihiko, Kawamura, Sadafumi, Ishidoya, Shigeto, Hoshi, Senji, Ishida, Masanori, Mizuno, Kei, Ogura, Keiji, Goto, Takayuki, Terada, Naoki, Kobayashi, Takashi, Yamasaki, Toshinari, Inoue, Takahiro, Tsuchiya, Norihiko, Ohyama, Chikara, Arai, Yoichi, Habuchi, Tomonori, Morita, Satoshi, and Ogawa, Osamu

Published
2019
Full Text
View/download PDF

8. Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer

Author

Hamano, Itsuto, Hatakeyama, Shingo, Narita, Shintaro, Takahashi, Masahiro, Sakurai, Toshihiko, Kawamura, Sadafumi, Hoshi, Senji, Ishida, Masanori, Kawaguchi, Toshiaki, Ishidoya, Shigeto, Shimoda, Jiro, Sato, Hiromi, Mitsuzuka, Koji, Tochigi, Tatsuo, Tsuchiya, Norihiko, Arai, Yoichi, Habuchi, Tomonori, and Ohyama, Chikara

Published
2019
Full Text
View/download PDF

9. Impact of nutritional status on the prognosis of patients with metastatic hormone-naïve prostate cancer: a multicenter retrospective cohort study in Japan

Author

Okamoto, Teppei, Hatakeyama, Shingo, Narita, Shintaro, Takahashi, Masahiro, Sakurai, Toshihiko, Kawamura, Sadafumi, Hoshi, Senji, Ishida, Masanori, Kawaguchi, Toshiaki, Ishidoya, Shigeto, Shimoda, Jiro, Sato, Hiromi, Mitsuzuka, Koji, Tochigi, Tatsuo, Tsuchiya, Norihiko, Arai, Yoichi, Habuchi, Tomonori, and Ohyama, Chikara

Published
2019
Full Text
View/download PDF

10. Prostate‐specific antigen follow‐up and management for patients undergoing holmium laser enucleation of the prostate.

Author

Kimura, Shingo, Katayama, Hiromichi, Ohara, Eiichiro, Aoki, Hiroshi, Shibuya, Rie, Naganuma, Hiroshi, Ishidoya, Shigeto, and Ito, Akihiro

Subjects
PROSTATE-specific antigen, SURGICAL enucleation, HOLMIUM, PROSTATE, WATCHFUL waiting
Abstract

Objectives: To investigate who needs a careful postoperative monitoring for prostate cancer (PCa) after holmium laser enucleation of the prostate (HoLEP). We examined characteristics and oncological outcomes of HoLEP‐related PCa. Methods: Patients who underwent HoLEP during 2002–2017 in a Japanese tertiary center were retrospectively analyzed. Patients were divided into non‐PCa, PCa with HoLEP specimen (PCa‐Ope), and PCa diagnosed during follow‐up (PCa‐Post). Outcomes of all HoLEP‐related PCa were monitored. Results: Of the total 758, 60 (7.9%) were diagnosed with PCa from resected specimen of HoLEP and 9 (1.2%) were diagnosed postoperatively. Preoperative prostate‐specific antigen (iPSA), postoperative PSA (pPSA), and PSA density were significantly higher in both PCa groups than those in non‐PCa group. While iPSA significantly correlated to prostate volume (PV), pPSA was not associated with PV. A receiver‐operating‐characteristics curve demonstrated that pPSA 1.2 ng/mL achieved the optimal cut‐off (AUC 0.95) for the incidence of PCa‐Post. In addition to the incidence of PCa and iPSA, lower enucleation efficiency (enucleated volume /PV) was significantly associated with pPSA >1.2 ng/mL. Among PCa‐Ope, 51 were Grade Group (GG) ≤2 and 42 were followed‐up with active surveillance, whereas 8 of 9 PCa‐Post were GG ≥3 and 2 progressed to death. Conclusions: Patients undergoing HoLEP are associated with some risk of potential PCa. While oncological outcomes were favorable among PCa‐Ope, postoperative PSA should be carefully monitored even if not diagnosed with PCa with HoLEP specimen. Enucleation efficiency should be also considered not to misread pPSA value. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Changes in conditional net survival and dynamic prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy

Author

Narita, Shintaro, Nomura, Kyoko, Hatakeyama, Shingo, Takahashi, Masahiro, Sakurai, Toshihiko, Kawamura, Sadafumi, Hoshi, Senji, Ishida, Masanori, Kawaguchi, Toshiaki, Ishidoya, Shigeto, Shimoda, Jiro, Sato, Hiromi, Mitsuzuka, Koji, Tochigi, Tatsuo, Tsuchiya, Norihiko, Ohyama, Chikara, Arai, Yoichi, Nagashima, Kengo, Habuchi, Tomonori, Narita, Shintaro, Nomura, Kyoko, Hatakeyama, Shingo, Takahashi, Masahiro, Sakurai, Toshihiko, Kawamura, Sadafumi, Hoshi, Senji, Ishida, Masanori, Kawaguchi, Toshiaki, Ishidoya, Shigeto, Shimoda, Jiro, Sato, Hiromi, Mitsuzuka, Koji, Tochigi, Tatsuo, Tsuchiya, Norihiko, Ohyama, Chikara, Arai, Yoichi, Nagashima, Kengo, and Habuchi, Tomonori

Abstract

Background The purpose of this study was to identify predictive factors associated with conditional net survival in patients with metastatic hormone-naive prostate cancer (mHNPC) initially treated with androgen deprivation therapy (ADT). Methods At nine hospitals in Tohoku, Japan, the medical records of 605 consecutive patients with mHNPC who initially received ADT were retrospectively reviewed. The Pohar Perme estimator was used to calculate conditional net cancer-specific survival (CSS) and overall survival (OS) for up to 5 years subsequent to the diagnosis. Using multiple imputation, proportional hazard ratios for conditional CSS and OS were calculated with adjusted Cox regression models. Results During a median follow up of 2.95 years, 208 patients died, of which 169 died due to progressive prostate cancer. At baseline, the 5-year CSS and OS rates were 65.5% and 58.2%, respectively. Conditional 5-year net CSS and OS survival gradually increased for all the patients. In patients given a 5-year survivorship, the conditional 5-year net CSS and OS rates improved to 0.906 and 0.811, respectively. Only the extent of disease score (EOD) >= 2 remained a prognostic factor for CSS and OS up to 5 years; as survival time increased, other variables were no longer independent prognostic factors. Conclusions The conditional 5-year net CSS and OS in patients with mHNPC gradually increased; thus, the risk of mortality decreased with increasing survival. The patient's risk profile changed over time. EOD remained an independent prognostic factor for CSS and OS after 5-year follow-up. Conditional net survival can play a role in clinical decision-making, providing intriguing information for cancer survivors.

Published
2023

12. Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer

Author

Narita, Shintaro, Nomura, Kyoko, Hatakeyama, Shingo, Takahashi, Masahiro, Sakurai, Toshihiko, Kawamura, Sadafumi, Hoshi, Senji, Ishida, Masanori, Kawaguchi, Toshiaki, Ishidoya, Shigeto, Shimoda, Jiro, Sato, Hiromi, Mitsuzuka, Koji, Tochigi, Tatsuo, Tsuchiya, Norihiko, Ohyama, Chikara, Arai, Yoichi, Nagashima, Kengo, Habuchi, Tomonori, Narita, Shintaro, Nomura, Kyoko, Hatakeyama, Shingo, Takahashi, Masahiro, Sakurai, Toshihiko, Kawamura, Sadafumi, Hoshi, Senji, Ishida, Masanori, Kawaguchi, Toshiaki, Ishidoya, Shigeto, Shimoda, Jiro, Sato, Hiromi, Mitsuzuka, Koji, Tochigi, Tatsuo, Tsuchiya, Norihiko, Ohyama, Chikara, Arai, Yoichi, Nagashima, Kengo, and Habuchi, Tomonori

Abstract

We evaluated the impact of early changes in serum biomarker levels on the survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC) who were initially treated with androgen deprivation therapy (ADT). We retrospectively investigated 330 patients with mHSPC whose serum maker levels were at baseline and at 2-4 months. An optimal Cox regression model was established with the highest optimism-corrected concordance index based on 10-fold cross-validation. The median cancer-specific survival (CSS) and overall survival (OS) were 7.08 and 6.47 years (median follow-up, 2.53 years), respectively. In the final optimal Cox model with serum biomarker levels treated as time-varying covariates, prostate-specific antigen (PSA), hemoglobin (Hb), and alkaline phosphatase (ALP) significantly increased the risk of poor survival in the context of both CSS and OS. Kaplan-Meier curves stratified by the three risk factors of high PSA, low Hb and high ALP desmondtated that median OS were not reached with none of these factors, 6.47 years with one or two factors, and 1.76 years with all three factors. Early changes in serum biomarker levels after ADT may be good prognostic markers for the survival of patients with mHSPC.

Published
2023

13. Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer

Author

Narita, Shintaro, Nomura, Kyoko, Hatakeyama, Shingo, Takahashi, Masahiro, Sakurai, Toshihiko, Kawamura, Sadafumi, Hoshi, Senji, Ishida, Masanori, Kawaguchi, Toshiaki, Ishidoya, Shigeto, Shimoda, Jiro, Sato, Hiromi, Mitsuzuka, Koji, Tochigi, Tatsuo, Tsuchiya, Norihiko, Ohyama, Chikara, Arai, Yoichi, Nagashima, Kengo, and Habuchi, Tomonori

Published
2019
Full Text
View/download PDF

14. Trends in the use of local intervention for metastatic hormone‐naïve prostate cancer: A multicenter retrospective study.

Author

Tanaka, Ryuma, Hatakeyama, Shingo, Narita, Shintaro, Sakurai, Toshihiko, Tanaka, Toshikazu, Miura, Hikari, Oishi, Takuya, Kawamura, Sadafumi, Hoshi, Senji, Ishidoya, Shigeto, Mitsuzuka, Koji, Ito, Akihiro, Tsuchiya, Norihiko, Habuchi, Tomonori, and Ohyama, Chikara

Subjects
PROSTATE cancer, ANDROGEN receptors, CASTRATION-resistant prostate cancer, ANDROGEN deprivation therapy, PROSTATE-specific antigen, RETROSPECTIVE studies
Abstract

Objective: To evaluated the trends of local intervention and their impact on oncological outcomes in metastatic hormone‐naïve prostate cancer (mHNPC) in real‐world practice. Methods: This retrospective multicenter study included 760 patients treated with either androgen deprivation therapy (ADT) without local treatment (no castration‐resistant prostate cancer [CRPC] progression within 12 months, control group) or ADT plus local intervention (intervention group) between January 2005 and March 2022. We evaluated the trends in the use of local intervention in patients with mHNPC and factors associated with CRPC‐free survival in the intervention group. Results: The use of local intervention gradually increased in combination with upfront combination treatment (docetaxel or androgen receptor axis‐targeted agents) for the duration of our study. The number of patients with local intervention combined with upfront treatment was significantly higher in patients with high tumor burden disease than in those with low tumor burden disease. Of the 108 patients who received local intervention, a duration of ≤7 months of initial therapy before local intervention and a level of prostate‐specific antigen ≥0.20 ng/mL at the time of local intervention were significantly associated with poor CRPC‐free survival. Conclusions: The use of local intervention in combination with upfront therapy to treat mHNPC increased for the duration of our study regardless of the tumor burden. Local intervention in addition to the standard of care for mHNPC may be a feasible treatment option for selected patients, taking into consideration the duration of and response to initial treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Minimal residual membranous urethral length and membranous urethral length predict poor recovery from incontinence after robot‐assisted radical prostatectomy and after open radical prostatectomy

Author

Ohara, Eiichiro, primary, Kawamorita, Naoki, additional, Satake, Yohei, additional, Kaiho, Yasuhiro, additional, Mitsuzuka, Koji, additional, Saito, Hideo, additional, Ishidoya, Shigeto, additional, Arai, Yoichi, additional, and Ito, Akihiro, additional

Published
2022
Full Text
View/download PDF

16. Effect of upfront intensive therapy on oncological outcomes in older patients with high tumor burden metastatic castration‐sensitive prostate cancer: A multicenter retrospective study

Author

Miura, Yuki, primary, Hatakeyama, Shingo, additional, Narita, Shintaro, additional, Kimura, Takahiro, additional, Hata, Kenichi, additional, Yanagisawa, Takafumi, additional, Tanaka, Toshikazu, additional, Ishi, Noritaka, additional, Kawamura, Sadafumi, additional, Hoshi, Senji, additional, Ishidoya, Shigeto, additional, Mitsuzuka, Koji, additional, Ito, Akihiro, additional, Tsuchiya, Norihiko, additional, Egawa, Shin, additional, Habuchi, Tomonori, additional, and Ohyama, Chikara, additional

Published
2022
Full Text
View/download PDF

19. PD35-11 THE IMPACT OF OLDER AGE ON THE ONCOLOGICAL OUTCOMES FOR HIGH-RISK METASTATIC HORMONE-SENSITIVE PROSTATE CANCER TREATED WITH UPFRONT INTENSIVE THERAPY

Author

Hatakeyama, Shingo, primary, Narita, Shintaro, additional, Kimura, Takahiro, additional, Hata, Kenichi, additional, Yanagisawa, Takafumi, additional, Tsuchiya, Norihiko, additional, Hoshi, Senji, additional, Ishidoya, Shigeto, additional, Kawamura, Sadafumi, additional, Ito, Akihiro, additional, Egawa, Shin, additional, Habuchi, Tomonri, additional, and Ohyama, Chikara, additional

Published
2022
Full Text
View/download PDF

23. Impact of Gleason pattern 5 on prognosis for newly diagnosed metastatic hormone‐sensitive prostate cancer with Gleason score ≥8

Author

Morozumi, Kento, primary, Mitsuzuka, Koji, additional, Narita, Shintaro, additional, Takahashi, Masahiro, additional, Kawamura, Sadafumi, additional, Tochigi, Tatsuo, additional, Arai, Yoichi, additional, Hoshi, Senji, additional, Shimoda, Jiro, additional, Ishidoya, Shigeto, additional, Okamoto, Teppei, additional, Hatakeyama, Shingo, additional, Sakurai, Toshihiko, additional, Tsuchiya, Norihiko, additional, Ohyama, Chikara, additional, Habuchi, Tomonori, additional, and Ito, Akihiro, additional

Published
2022
Full Text
View/download PDF

26. Laparoscopic Adrenalectomy Is Beneficial for the Health-Related Quality of Life of Older Patients with Primary Aldosteronism.

Author

Kawasaki, Yoshihide, Ishidoya, Shigeto, Morimoto, Ryo, Ono, Yoshikiyo, Omata, Kei, Tezuka, Yuta, Kawamorita, Naoki, Yamashita, Shinichi, Mitsuzuka, Koji, Satoh, Fumitoshi, and Ito, Akihiro

Subjects
*OLDER patients, *QUALITY of life, *ADRENALECTOMY, *HYPERALDOSTERONISM, *LAPAROSCOPIC surgery
Abstract

Objective: Laparoscopic adrenalectomy (LADX) improves hypertension in patients with primary aldosteronism (PA). However, the antihypertensive impact of LADX appears restricted in older patients with PA. In this study, we evaluated the impact of LADX in older patients focusing on the health-related quality of life (HRQoL). Methods: A total of 156 patients with PA who underwent LADX in a single institution were enrolled in this prospective cohort study. The patients were divided into 2 groups, with a boundary of 60 years. The HRQoL was evaluated using the Medical Outcomes Study's 36-Item Short-Form Health Survey version 2 (SF-36v2) questionnaire before and after LADX. Demographics, clinical features, antihypertensive drugs before and after surgery, and perioperative evaluation were recorded. We compared all scale scores and summed scores between groups. Multivariate regression models were used to determine the associations between various covariables and the HRQoL. Results: In the older PA patients, most subscales of HRQoL at baseline were lower than the national standard values. The antihypertensive drug-free rate by LADX was only 21% in older patients, compared to 58% in younger patients. However, a significant improvement in mental HRQoL was observed after LADX (p = 0.002). The much preoperative antihypertensive drugs, lower preoperative potassium level, and smaller degree of comorbidities were predictors of improved mental HRQoL by LADX on multivariate analyses. Conclusion: The older PA patients showed lower mental HRQOL than the national standard populations. Although antihypertensive effects were limited for these patients, LADX was beneficial as PA treatment via improvement of mental HRQoL. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

27. MP32-07 CHANGES IN THE CONDITIONAL NET SURVIVAL AND DYNAMIC PROGNOSTIC FACTORS IN PATIENTS WITH NEWLY DIAGNOSED METASTATIC PROSTATE CANCER

Author

Narita, Shintaro, primary, Nomura, Kyoko, additional, Hatakeyama, Shingo, additional, Takahashi, Masahiro, additional, Sakurai, Toshihiko, additional, Kawamura, Sadafumi, additional, Hoshi, Senji, additional, Ishida, Masanori, additional, Kawaguchi, Toshiaki, additional, Ishidoya, Shigeto, additional, Shimoda, Jiro, additional, Sato, Hiromi, additional, Mituzuka, Koji, additional, Tochigi, Tatsuo, additional, Tsuchiya, Norihiko, additional, Ohyama, Chikara, additional, Arai, Yoichi, additional, Nagashima, Kengo, additional, and Habuchi, Tomonori, additional

Published
2021
Full Text
View/download PDF

33. Additional file 1 of Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study

Author

Okamoto, Teppei, Noro, Daisuke, Hatakeyama, Shingo, Narita, Shintaro, Mitsuzuka, Koji, Sakurai, Toshihiko, Sadafumi Kawamura, Senji Hoshi, Shimoda, Jiro, Tanaka, Toshikazu, Kawaguchi, Toshiaki, Ishidoya, Shigeto, Ito, Akihiro, Norihiko Tsuchiya, Habuchi, Tomonori, and Ohyama, Chikara

Abstract

Additional file 1: Figure S1. Patient selection. We retrospectively evaluated 168 mHSPC patients with high tumor burden who were initially treated with ADT alone or CAB (ADT/CAB, n = 101) or upfront ABI therapy (n = 67) in the Aomori database. Furthermore, we retrospectively evaluated 563 mHSPC patients with high-volume disease, as reported in the CHAARTED trial, in the Michinoku database. We excluded 44 patients who were treated with ADT/CAB in the Aomori database and 485 patients in the Michinoku database due to old era of initial diagnosis (22 patients in the Aomori database and 131 in the Michinoku database) or insufficient baseline laboratory data or (22 patients in the Aomori database and 354 in the Michinoku database). Figure S2 Comparison of clinical progression in the entire cohort and multivariate logistic analysis for pretreatment anemia. (A) PFS between patients in the upfront ABI and ADT/CAB groups and those in the entire cohort (median, not reached vs. 10 months; P

Published
2021
Full Text
View/download PDF

43. Therapeutic effects of the combined androgen blockade therapy versus luteinizing hormone-releasing hormone analog monotherapy in patients with hormone naïve metastatic prostate cancer: a multi-institutional comparative analysis

Author

Narita, Takuma, primary, Hatakeyama, Shingo, additional, Narita, Shintaro, additional, Takahashi, Masahiro, additional, Sakurai, Toshihiko, additional, Kawamura, Sadafumi, additional, Hoshi, Senji, additional, Shimoda, Jiro, additional, Kawaguchi, Toshiaki, additional, Ishidoya, Shigeto, additional, Mitsuzuka, Koji, additional, Arai, Yoichi, additional, Ito, Akihiro, additional, Tsuchiya, Norihiko, additional, Habuchi, Tomonori, additional, and Ohyama, Chikara, additional

Published
2021
Full Text
View/download PDF

47. Cosyntropin-Stimulated ‘Superselective’ Adrenal Venous Sampling Reveals Suppressed Aldosterone Secretion from Both Attached Non-Neoplastic Parts of Ipsilateral Adrenal Gland and Contralateral Adrenal Gland in Primary Aldosteronism Due to Unila

Author

Morimoto, Ryo, primary, Satoh, Fumitoshi, additional, Kudo, Masataka, additional, Iwakura, Yoshitsugu, additional, Ono, Yoshikiyo, additional, Murakami, Osamu, additional, Takase, Kei, additional, Ishidoya, Shigeto, additional, Nakamura, Yasuhiro, additional, Sasano, Hironobu, additional, and Ito, Sadayoshi, additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results